Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics

10x Genomics (TXG) reported $166.03 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 0.6%. EPS of -$0.13 for the same period compares to -$0.40 a year ago.

The reported revenue represents a surprise of +0.01% over the Zacks Consensus Estimate of $166.01 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +31.58%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Services: $8.47 million versus the four-analyst average estimate of $7.78 million. The reported number represents a year-over-year change of +18.7%.
• Revenues- Instruments: $15.47 million versus the three-analyst average estimate of $14.4 million. The reported number represents a year-over-year change of -36.5%.
• Revenues- Consumables- Spatial: $40.96 million compared to the $39.03 million average estimate based on three analysts. The reported number represents a change of +14.4% year over year.
• Revenues- Consumables: $141.75 million versus $134.78 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
• Revenues- Instruments- Spatial: $9.36 million versus $7.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30.3% change.

View all Key Company Metrics for 10x Genomics here>>>

Shares of 10x Genomics have returned -8.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
10x Genomics (TXG): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research